A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Milademetan (Primary)
Indications Diffuse large B cell lymphoma; Liposarcoma; Lymphoma; Malignant melanoma; Sarcoma; Solid tumours; Synovial sarcoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc

23 Mar 2023 Results assessing the safety profile and management of adverse events of milademetan from U101; NCT01877382 and MANTRA-2; NCT05012397 studies, presented at the British Sarcoma Group (BSG) Conference.
21 Mar 2023 According to Rain Oncology media release, a copy of the presentation materials containing data from this study can be accessed by visiting the Resources section of the Rain website after the conclusion of the presentation and will be archived on the Rain website
23 Jan 2023 Results published in the Rain Oncology media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com